[1]CurrentPatentAssignee:SHENYANGPHARMACEUTICALUNIVERSITY-CN104072498,2016,BLocationinpatent:Paragraph0064;0065;0080;0093;0110;0124;0157
[2]Fancelli,Daniele;Moll,Jürgen;Varasi,Mario;Bravo,Rodrigo;Artico,Roberta;Berta,Daniela;Bindi,Simona;Cameron,Alexander;Candiani,Ilaria;Cappella,Paolo;Carpinelli,Patrizia;Croci,Walter;Forte,Barbara;Giorgini,MariaLaura;Klapwijk,Jan;Marsiglio,Aurelio;Pesenti,Enrico;Rocchetti,Maurizio;Roletto,Fulvia;Severino,Dino;Soncini,Chiara;Storici,Paola;Tonani,Roberto;Zugnoni,Paola;Vianello,Paola[JournalofMedicinalChemistry,2006,vol.49,#24,p.7247-7251]
[3]CurrentPatentAssignee:NERVIANOMEDICALSCIENCESS.R.L.-WO2005/5427,2005,A1Locationinpatent:Page/Pagecolumn25
[1]JournalofMedicinalChemistry,2006,vol.49,p.7247-7251
[2]Patent:CN104072498,2016,B
[1]JournalofMedicinalChemistry,2006,vol.49,p.7247-7251
[2]Patent:CN104072498,2016,B
[1]Fancelli,Daniele;Moll,Jürgen;Varasi,Mario;Bravo,Rodrigo;Artico,Roberta;Berta,Daniela;Bindi,Simona;Cameron,Alexander;Candiani,Ilaria;Cappella,Paolo;Carpinelli,Patrizia;Croci,Walter;Forte,Barbara;Giorgini,MariaLaura;Klapwijk,Jan;Marsiglio,Aurelio;Pesenti,Enrico;Rocchetti,Maurizio;Roletto,Fulvia;Severino,Dino;Soncini,Chiara;Storici,Paola;Tonani,Roberto;Zugnoni,Paola;Vianello,Paola[JournalofMedicinalChemistry,2006,vol.49,#24,p.7247-7251]
[2]CurrentPatentAssignee:SHENYANGPHARMACEUTICALUNIVERSITY-CN104072498,2016,B
[1]Fancelli,Daniele;Moll,Jürgen;Varasi,Mario;Bravo,Rodrigo;Artico,Roberta;Berta,Daniela;Bindi,Simona;Cameron,Alexander;Candiani,Ilaria;Cappella,Paolo;Carpinelli,Patrizia;Croci,Walter;Forte,Barbara;Giorgini,MariaLaura;Klapwijk,Jan;Marsiglio,Aurelio;Pesenti,Enrico;Rocchetti,Maurizio;Roletto,Fulvia;Severino,Dino;Soncini,Chiara;Storici,Paola;Tonani,Roberto;Zugnoni,Paola;Vianello,Paola[JournalofMedicinalChemistry,2006,vol.49,#24,p.7247-7251]
Title: Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance.
Journal: Journal of molecular biology 20170217
Title: Inhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cells.
Journal: PloS one 20140101
Title: Identification of potent Yes1 kinase inhibitors using a library screening approach.
Journal: Bioorganic & medicinal chemistry letters 20130801
Title: Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML.
Journal: Nature chemical biology 20121101
Title: Targeting aurora kinases with danusertib (PHA-739358) inhibits growth of liver metastases from gastroenteropancreatic neuroendocrine tumors in an orthotopic xenograft model.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20120901
Title: Danusertib, an aurora kinase inhibitor.
Journal: Expert opinion on investigational drugs 20120301
Title: Transcriptional analysis of the Aurora inhibitor Danusertib leading to biomarker identification in TP53 wild type cells.
Journal: Gene 20120225
Title: In vitro drug metabolism by C-terminally truncated human flavin-containing monooxygenase 3.
Journal: Biochemical pharmacology 20120215
Title: Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia.
Journal: Clinical Medicine Insights. Oncology 20120101
Title: Tyrosine kinase inhibitors in hematological malignancies.
Journal: Postepy higieny i medycyny doswiadczalnej (Online) 20111205
Title: Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib.
Journal: Investigational new drugs 20111001
Title: An integrated chemical biology approach identifies specific vulnerability of Ewing's sarcoma to combined inhibition of Aurora kinases A and B.
Journal: Molecular cancer therapeutics 20111001
Title: New drugs for chronic myelogenous leukemia.
Journal: Current hematologic malignancy reports 20110601
Title: The molecular mechanism studies of chirality effect of PHA-739358 on Aurora kinase A by molecular dynamics simulation and free energy calculations.
Journal: Journal of computer-aided molecular design 20110201
Title: Abcg2 overexpression represents a novel mechanism for acquired resistance to the multi-kinase inhibitor Danusertib in BCR-ABL-positive cells in vitro.
Journal: PloS one 20110101
Title: Dynamics of resistance development to imatinib under increasing selection pressure: a combination of mathematical models and in vitro data.
Journal: PloS one 20110101
Title: Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.
Journal: Cancer research 20101201
Title: A type-II kinase inhibitor capable of inhibiting the T315I 'gatekeeper' mutant of Bcr-Abl.
Journal: Journal of medicinal chemistry 20100812
Title: Identification of Myb-binding protein 1A (MYBBP1A) as a novel substrate for aurora B kinase.
Journal: The Journal of biological chemistry 20100416
Title: Aurora kinase inhibitors as anti-cancer therapy.
Journal: Anti-cancer drugs 20100401
Title: Danusertib (formerly PHA-739358)--a novel combined pan-Aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor.
Journal: Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20100101
Title: Optimizing combination therapies with existing and future CML drugs.
Journal: PloS one 20100101
Title: A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20091101
Title: Overcoming resistance in chronic myelogenous leukemia.
Journal: Leukemia & lymphoma 20091101
Title: Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091020
Title: Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.
Journal: Neoplasia (New York, N.Y.) 20090901
Title: Discovery and development of aurora kinase inhibitors as anticancer agents.
Journal: Journal of medicinal chemistry 20090514
Title: Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I.
Journal: Blood 20080415
Title: Aurora kinase A inhibitors: identification, SAR exploration and molecular modeling of 6,7-dihydro-4H-pyrazolo-[1,5-a]pyrrolo[3,4-d]pyrimidine-5,8-dione scaffold.
Journal: Bioorganic & medicinal chemistry letters 20080301
Title: Inhibitors of ABL and the ABL-T315I mutation.
Journal: Current topics in medicinal chemistry 20080101
Title: PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.
Journal: Molecular cancer therapeutics 20071201
Title: Crystal structure of the T315I Abl mutant in complex with the aurora kinases inhibitor PHA-739358.
Journal: Cancer research 20070901
Title: 1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.
Journal: Journal of medicinal chemistry 20061130
Title: Zi D, et al. Danusertib Induces Apoptosis, Cell Cycle Arrest, and Autophagy but Inhibits Epithelial to Mesenchymal Transition Involving PI3K/Akt/mTOR Signaling Pathway in Human Ovarian Cancer Cells. Int J Mol Sci. 2015 Nov 13;16(11):27228-51.
Title: Gontarewicz A, et al. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood. 2008 Apr 15;111(8):4355-64.
Title: Fraedrich K, et al. Targeting Aurora Kinases with Danusertib (PHA-739358) Inhibits Growth of Liver Metastases from Gastroenteropancreatic Neuroendocrine Tumors in an Orthotopic Xenograft Model. Clin Cancer Res. 2012 Sep 1;18(17):4621-32. Epub 2012 Jul 2.
